Efficacy and safety of Songling Xuemaikang capsule for essential hypertension: A systematic review and meta-analysis of randomized controlled trials

Meng, Tiantian; Wang, Peng; Xie, Xiaolong; Kong, Lingbo; Xu, Ying-Zhi; Cao, Kegang; Gao, Ying; He, Qingyong; Lai, Xinxing

doi:10.1016/j.phymed.2022.154459

Cited by 8 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirteen studies [60][61][62][63][64][65][66][67][68][69][70][71][72] met the selection criteria, and 2 unique outcomes were enrolled (Fig. 6).…”

Section: Htmentioning

confidence: 99%

The efficacy of traditional Chinese herbal medicine across multiple cardiovascular diseases: an umbrella review of systematic reviews of randomized controlled trials

Li,

Yu,

Jiang

et al. 2024

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Traditional Chinese herbal medicine (CHM) has been extensively used in cardiovascular disease in modern clinical practice, alone or in combination with conventional treatment. However, its efficacy has not been assessed extensively. From inception until August 2023, we systematically searched five public literature databases to conduct the umbrella review. The inclusion criterion is systematic reviews of randomized controlled trials investigating the effect of CHM in the contemporary management of cardiovascular diseases. The quality of the included systematic reviews, the certainty of the evidence, and the potential risk of bias were assessed. Five hundred and thirty-nine systematic reviews, including 346 studies in Chinese and 193 in English, were selected before the quantitative synthesis. The methodological quality was generally moderate, with a median value of 11. The favorable efficacy of CHM was primarily presented on five main conditions, coronary artery disease, hypertension, heart failure, restenosis, and angina pectoris. CHM, with or without conventional treatment, showed a consistent beneficial effect in various cardiovascular diseases. Nevertheless, the magnitude of the effect requires further investigation as the lack of relevant research and the complexity of the clinical practice of CHM.

show abstract

“…Thirteen studies [60][61][62][63][64][65][66][67][68][69][70][71][72] met the selection criteria, and 2 unique outcomes were enrolled (Fig. 6).…”

Section: Htmentioning

confidence: 99%

The efficacy of traditional Chinese herbal medicine across multiple cardiovascular diseases: an umbrella review of systematic reviews of randomized controlled trials

Li,

Yu,

Jiang

et al. 2024

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

“…Despite considerable advancements in pharmacological interventions, the treatment and control of hypertension continue to be suboptimal. In recent years, emerging evidence has highlighted the potential of herbal medicine as an alternative therapeutic approach for hypertension ( Lai et al, 2022 ; Meng et al, 2022 ).…”

Section: Hypertensionmentioning

confidence: 99%

“…In recent years, herbal medicines have increasingly demonstrated their potential as alternative therapies for cardiovascular-related diseases ( Chen et al, 2022 ; Lai et al, 2022 ; Meng et al, 2022 ). However, given the scarcity of clinical evidence, further investigation is warranted to elucidate the efficacy and underlying mechanisms of herbal medicine in treating CVDs.…”

Section: Introductionmentioning

confidence: 99%

Editorial: Efficacy and mechanism of herbal medicines and their functional compounds in preventing and treating cardiovascular diseases and cardiovascular disease risk factors

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…For instance, Ilex hainanensis Merr., also known as Shan-Lv medicine, when paired with antihypertensive drugs, exhibits enhanced efficacy in blood pressure reduction than standalone drug treatments (Yang et al, 2018). Similarly, the Songling Xuemaikang Capsule combined with conventional medicine has demonstrated clear efficacy and safety for EH management (Meng et al, 2022). Over the years, pharmacological management of hypertension has advanced.…”

Section: Introductionmentioning

confidence: 99%

Chinese patent medicine combined with calcium channel blockers in the treatment of essential hypertension:a Bayes network meta-analysis and systematic review

Cui,

Liu,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Backgroud: The co-administration of Chinese patent medicine with calcium channel blockers (CCBs) is a prevalent practice in China for treating essential hypertension (EH). However, robust evidence supporting the efficacy and safety of tailored combinations of different Chinese patent medicines with CCBs, according to individual patient conditions, is still limited. This study sought to elucidate the efficacy and safety of these combinations using a systematic review and network meta-analysis.Materials and methods: Relevant studies were sourced from established databases, incorporating randomized controlled trials published up to 1 February 2023. The ROB2 tool from the Cochrane Collaborative Network was employed to independently assess and cross-verify the quality of the included literature. A network meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 and PRISMA-Network Meta-Analyses (PRISMA-NMA) guidelines. A Bayesian network meta-analysis was utilized to gauge the efficacy and safety of distinct integrations of Chinese patent medicine and CCBs. Primary outcomes were interpreted using a paired fixed-effect meta-analysis. Publication bias was appraised through Egger’s test and represented with funnel plots. All statistical analyses were executed within the R statistical framework.Results: Following rigorous selection, data extraction, and bias evaluation, 36 articles were incorporated. Tianma Gouteng Granule, when combined with CCBs, displayed superior efficacy in reducing systolic blood pressure (SBP). In terms of diastolic blood pressure (DBP) reduction, Songling Xuemaikang Capsule combined with CCBs emerged as the most effective. Regarding enhancement of antihypertensive effective rates, Qinggan Jiangya Capsule paired with CCBs demonstrated optimal results. For diminishing Traditional Chinese Medicine syndrome scores, the Qiangli Dingxuan Tablet and CCBs combination proved most beneficial. When aiming to reduce total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, Tianma Gouteng Granule and CCBs showcased superior results. In contrast, the combination of Songling Xuemaikang Capsule and CCBs was more effective in reducing LDL-C, tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6).Conclusion: This study underscores variability in outcomes from combining Chinese patent medicine and CCBs for hypertension, emphasizing the importance of personalized medicinal combinations, especially Tianma Gouteng Granule and Songling Xuemaikang Capsule. The results offer robust evidence to inform clinical guidelines for essential hypertention and significantly aid clinician in seleting appropriate Chinese patent medicines for treatment.

show abstract

Efficacy and safety of Songling Xuemaikang capsule for essential hypertension: A systematic review and meta-analysis of randomized controlled trials

Cited by 8 publications

References 39 publications

The efficacy of traditional Chinese herbal medicine across multiple cardiovascular diseases: an umbrella review of systematic reviews of randomized controlled trials

The efficacy of traditional Chinese herbal medicine across multiple cardiovascular diseases: an umbrella review of systematic reviews of randomized controlled trials

Editorial: Efficacy and mechanism of herbal medicines and their functional compounds in preventing and treating cardiovascular diseases and cardiovascular disease risk factors

Chinese patent medicine combined with calcium channel blockers in the treatment of essential hypertension:a Bayes network meta-analysis and systematic review

Contact Info

Product

Resources

About